Refine by
Pediatric Patients Articles & Analysis
89 news found
These cutting-edge drug delivery technologies enhance therapeutic efficiency and patient compliance, offering a versatile alternative to conventional tablets and capsules. ...
At best, most of us tolerate needles. Whether a vaccine, an IV drip, or a blood draw, we can talk ourselves through it with the knowledge that it is for the greater good and will only cause temporary discomfort. On the other side of the spectrum, there are people with such an intense fear of needles that they are considered to have a phobia, trypanophobia to be precise. Many articles have been ...
“We are truly delighted by this milestone, which will make this important medication available to millions of patients in Canada.” Ontario-based KYE Pharmaceuticals, Inc. will make Quillivant ER Oral Suspension and Quillivant ER Chewable Tablets available to patients in Canada beginning in Q1 2024. Tris will manufacture Quillivant ER in the United ...
The second-generation, FDA-cleared ReFlow Mini Flusher is indicated for use in patients living with hydrocephalus or similar conditions. The reduced size and profile of the technology is designed to better support a broader hydrocephalus patient population, from infants to older adults. ...
” Bill Heiden, Third Pole’s Chairman added, “This strategic investment in Third Pole Therapeutics is directly aligned with both organization’s mission to advance unique, disruptive, cost-effective solutions that improve outcomes in heart and lung-failure patients. It also provides validation that Third Pole’s technology represents the best in ...
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
“Timely treatment in this vulnerable pediatric patient population is crucial and we hope that we will soon be able to provide an additional therapeutic ...
ByBayer AG
Meshinchi is Professor, Clinical Research Division, at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology, at the University of Washington School of Medicine. “As a patient-driven company, we at Sutro are extremely pleased that STRO-002— which we are presently developing in ovarian cancer—had a ...
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - ...
Kerendia is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and CV outcomes in patients with CKD and T2D. Patients with visceral adiposity have been shown previously to respond better to MR antagonists than patients without visceral adiposity. ...
ByBayer AG
” “Since their inception, the UofL Health – Brown Cancer Center GMP Manufacturing Facility and the Dunbar CAR T-Cell Program at the University of Louisville have been committed to bringing these lifesaving immunotherapies to adult and pediatric cancer patients throughout Kentucky and the region. This manufacturing agreement with IN8bio will ...
Yet, the barriers to care are high with only 11% of patients who have OUD receiving the MOUD they need.2 Additionally, OUD relapse is common amongst patients. ...
FIGARO-DKD is the first contemporary Phase III CV outcomes trial to show CV benefit in a patient population where the majority of patients was in earlier CKD stages (stages 1-2 CKD, defined as estimated glomerular filtration rate [eGFR] ≥60 ml/min/1.73m2) with albuminuria. ...
ByBayer AG
xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). ...
ByxCures
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
“We are proud soon to be able to offer physicians a new, disease-modifying intervention improving patients’ outcomes, by delaying their chronic kidney disease ...
ByBayer AG
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial 100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate All patients showed clinical reversal of disease course, including statistically significant reduction in all-cause hospitalizations and incidence of ...